Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

gemcitabine/SU5416

Known as: dFdC/SU-5416 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Rationale: The pathogenesis of pulmonary arterial hypertension (PAH) involves remodelling of the pulmonary arteries, increased… Expand
Is this relevant?
2017
2017
Background: SUGEN/hypoxia (SuHx) causes pulmonary hypertension (PH) in rats. Cardiac MR (CMR) is the gold standard for… Expand
Is this relevant?
2016
2016
The SU5416 + hypoxia (SuHx) rat model is a commonly used model of severe pulmonary arterial hypertension. While it is known that… Expand
Is this relevant?
Review
2012
Review
2012
In spite of treatment, severe angioproliferative pulmonary arterial hypertension (PAH) remains a disease characterized by great… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
AIM To explore the effect of VEGF inhibitor SU5416 on podocytopathy of rats with type I diabetic nephropathy. METHODS Thirty… Expand
Is this relevant?
2007
2007
Potential prodrugs of inhibitors of VEGF-induced angiogenesis have been investigated. The prodrug systems studied were the 4… Expand
Is this relevant?
Review
2006
Review
2006
SU5416, 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, is a potent inhibitor of vascular endothelial growth… Expand
Is this relevant?
2005
2005
SummaryVascular endothelial growth factor (VEGF) is a potent stimulant of angiogenesis. SU5416, is a small molecule tyrosine… Expand
  • table 2
  • table 1
  • table 3
  • table 4
Is this relevant?
2004
2004
SU5416 is a selective inhibitor of vascular endothelial growth factor (VEGF) receptor, which plays a major role in vascular… Expand
Is this relevant?
2000
2000
SU5416 [3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1, 3-dihydro-indol-2-one], an inhibitor of VEGF (vascular endothelial growth… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?